FOLD•benzinga•
Amicus Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 revenue growth guidance.
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 6, 2024 by benzinga